Paper Details

  1. Home
  2. Paper Details

Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.

Author: BoccardoF, DecensiA U, FiorettoL, GiulianiL, GuarneriD, MacalusoM P, MartoranaG, MiniE, PeritiP, SantiL

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

A multicentric pilot study using the pure nonsteroidal antiandrogen nilutamide (Anandron--RU 23908) in 48 patients with stage D prostate carcinoma demonstrated a positive response in 43 evaluable patients. Overall, 41.6% of untreated patients achieved a partial response and 54.1% had stationary disease. In pretreated patients, 73.6% achieved stationary disease. Median progression-free survival in untreated patients was 325 days and overall survival was 696 days. The most common side effects were gastrointestinal toxicity (65%), hemeralopia (27%), and alcohol intolerance (6.2%).
Paper Details　
Original Abstract of the Article :
Between March 1986 and March 1987, 48 patients with stage D prostate carcinoma were entered into a multicentric pilot study using the pure nonsteroidal antiandrogen nilutamide (Anandron--RU 23908) at the dose of 100 mg t.i.d. as the only therapy until disease progression or the occurrence of toxicit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1782640

データ提供：米国国立医学図書館（NLM）

Anandron (Nilutamide) for Metastatic Prostate Cancer: A Promising Therapeutic Option

Prostate cancer is a significant health concern, and finding effective treatments for advanced stages of the disease is crucial. This study investigates the efficacy and safety of nilutamide (Anandron), a nonsteroidal antiandrogen, in patients with stage D prostate carcinoma. The researchers conducted a multicentric pilot study to evaluate the effectiveness of nilutamide as a single-agent therapy in this patient population.

Nilutamide: A Potential Oasis in the Desert of Prostate Cancer

The study reveals that nilutamide demonstrates promising efficacy in treating advanced prostate cancer, achieving partial response in a significant proportion of untreated patients and stabilizing disease progression in both untreated and pretreated patients. It’s like finding a refreshing oasis in the vast and unforgiving desert of advanced prostate cancer, offering a source of hope and potential for improved survival and quality of life.

Navigating the Complexities of Prostate Cancer Treatment

The study acknowledges the importance of managing potential side effects associated with nilutamide, including gastrointestinal toxicity, hemeralopia (day blindness), and alcohol intolerance. It’s like navigating a desert landscape where careful planning and awareness of potential dangers are crucial to reaching one's destination. The study highlights the importance of continued research and clinical monitoring to optimize treatment strategies and minimize potential adverse effects of nilutamide therapy.

Dr.Camel's Conclusion

The study provides valuable insights into the efficacy and safety of nilutamide (Anandron) as a treatment option for patients with advanced prostate cancer. The findings suggest that nilutamide may offer a valuable therapeutic approach for this challenging condition, offering hope for improved survival and quality of life. It's like discovering a new path through the desert of prostate cancer, offering a more effective and well-tolerated approach for managing this serious disease.
Date :
  1. Date Completed 1992-03-17
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

1782640

DOI: Digital Object Identifier

1782640

Related Literature

Article Analysis
・Side Effects of nilutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.